Allergen immunotherapy for the polyallergic patient.

Area of Science:

• Allergy and Immunology
• Immunotherapy
• Molecular Diagnostics

Background:

• Sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) are evolving with new monocomponent allergen products.
• Traditionally, compounded allergen mixtures were used for polyallergic patients, raising concerns about sufficiency of single-source products.

Purpose of the Study:

• To assess the impact of new diagnostic tools and standardized immunotherapy products on allergy treatment practices.
• To evaluate the necessity of compounded allergen extracts for polyallergic patients.

Main Methods:

• Review of current trends in allergy treatment and immunotherapy product development.
• Analysis of the implications of molecular IgE testing for diagnosing polysensitization.
• Consideration of survey data (e.g., Allermix) on allergist treatment preferences.

Main Results:

• Molecular IgE testing helps differentiate true polyallergy from pseudo-polyallergy.
• Registered, single-component allergen products are predicted to meet the needs of most polysensitized patients.
• Compounding of allergen mixtures may still be required for a small subset of patients with multiple independent allergies.

Conclusions:

• Standardized immunotherapy, guided by molecular diagnostics, can adequately manage the majority of polyallergic patients.
• The shift towards pharmaceutical-grade, monocomponent products is reshaping immunotherapy practices.
• A limited portfolio of registered allergen products is likely sufficient for current allergist treatment habits.